Table 1.
Characteristics of kidney transplantation recipients of the 2 study groups
| Characteristics | Control group (n = 63) | Genotype‐guided group (n = 62) |
|---|---|---|
| Age, mean ± SD (y) | 40.68 ± 10.57 | 41.77 ± 9.84 |
| Male sex, n (%) | 43 (68.3) | 37 (59.7) |
| Underlying diseases, n (%) | ||
| Hypertension | 26 (41.3) | 29 (46.8) |
| Chronic glomerulonephritis | 6 (9.5) | 11 (17.7) |
| Renal stone | 6 (9.5) | 3 (4.8) |
| Diabetes mellitus | 4 (6.3) | 2 (3.2) |
| Gout | 3 (4.8) | 1 (1.6) |
| Polycystic kidney disease | 1 (1.6) | 1 (1.6) |
| Unknown cause | 17 (27.0) | 15 (24.2) |
| Mode of previous dialysis, n (%) | ||
| Haemodialysis | 49 (77.8) | 39 (62.9) |
| Peritoneal dialysis | 14 (22.2) | 23 (37.1) |
| Duration of dialysis, mean ± SD (months) | 57.17 ± 38.59 | 62.05 ± 36.40 |
| Genotype of CYP3A5, n (%) | ||
| *1/*1 | 8 (12.7) | 8 (12.9) |
| *1/*3 | 28 (44.4) | 31 (50.0) |
| *3/*3 | 27 (42.9) | 23 (37.1) |
| ABO blood group, % | ||
| A/B/AB/O | 17.5/33.3/9.5/39.7 | 21.0/32.2/9.7/37.1 |
| Panel reactive antibody, mean ± SD (%) | 8.52 ± 22.18 | 10.37 ± 25.74 |
| Number of HLA mismatches, n (%) | ||
| ≥2 mismatches | 49 (77.8) | 41 (66.1) |
| Number of HLA‐DR mismatches, % | ||
| 0/1/2 mismatches | 58.7/38.1/3.2 | 53.2/46.8/0 |
| Ischaemic time, mean ± SD (h:min) | 16:45 ± 4:44 | 17:56 ± 4:90 |
| Receiving IL2 antagonist, n (%) | 31 (49.2) | 38 (61.3) |
| Receiving ATG, n (%) | 3 (4.8) | 1 (1.6) |
ATG, antithymocyte globulin; HLA, human leucocyte antigen; IL2, interleukin 2; SD; standard deviation.